Spesolimab

佩索利单抗

Report date: 2026/04/20 20:01:59
First In Class

Base Information

Drug NameSpesolimab
Drug Alias Name司柏索利单抗注射液Spesolimab-SBZO司柏索利单抗圣利卓Spevigo +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-36 receptor inhibitors
TargetsInterleukin-36 receptor
Therapy Area/IndicationsPalmoplantar pustulosisGeneralised pustular psoriasisPsoriasis +[9] 
Global Approved IndicationsPsoriasis
Approved Indications in ChinaPsoriasis
Original Approved Country/TerritoryUnited States
Original Approved Date2022/09/01
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgNippon Boehringer Ingelheim Co LtdBoehringer Ingelheim Pharma Gmbh & Co Kg +[7] 
Inactive CompaniesN/A
Active IndicationsGeneralised pustular psoriasisPsoriasisPyoderma Gangrenosum +[5] 
Inactive IndicationsPalmoplantar pustulosisDermatitis, AtopicNetherton Syndrome +[4] 

Other Information

ATC CodeN/A
Related LinksN/A